mRNA Therapeutics Market Worth USD 52.76 Billion By 2030 | CAGR: 4.7%

Latest Study on “mRNA Therapeutics Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2022-2030”.

The global mRNA Therapeutics market size is expected to be worth around USD 52.76 billion by 2030, according to a new report by Nova one advisor.

The global mRNA Therapeutics market size was valued at USD 39.91 billion in 2021 and is anticipated to grow at a CAGR of 4.7% during forecast period 2022 to 2030.

Get the Free Sample Copy of Report@ https://www.novaoneadvisor.com/report/sample/6847

RNA-based therapeutics have attracted a lot of attention in recent years owing to their high potential in treating chronic diseases. Furthermore, in terms of production, distribution, and safety, RNA vaccines provide a number of benefits over DNA vaccines. They have also shown promise in human clinical studies, which has increased the demand for mRNA vaccines and therapeutics. In addition, the number of mRNA-based vaccine therapeutics in oncology clinical trials has dramatically expanded as a result of the success of Moderna’s and Pfizer- BioNTech’s vaccines against COVID-19. Furthermore, barring the COVID-19 trials in cancer patients, 2021 has seen the second-highest number of mRNA vaccine trials for cancer patients, thus propelling the industry growth.

Due to the rising number of COVID-19 patients around the world and the significant external financing for the manufacturing of mRNA-based COVID-19 vaccines, the COVID-19 pandemic has favorably impacted the growth of the global market. Additionally, when new strains of the SARS-COVID-19 virus appear in numerous nations throughout the world, demand for mRNA vaccines witness a sharp rise due to their potent protection against these strains. As a result, the usage of these mRNA-based products is projected to increase during the COVID-19 pandemic and result in market growth.

Furthermore, messenger RNAs have become a promising therapeutic tool owing to recent technological advancements such as improved stability, translation, and delivery techniques. Indeed, mRNA vaccines have paved the way for new pharmacological areas and emerged as a prominent therapeutic class. These mRNA vaccines support next-generation vaccinations, ushering in a new era in vaccine development. For instance, in March 2020, Moderna, Inc. and the National Institute of Allergy and Infectious Diseases jointly developed the mRNA-1273 (NIAID). It shows 94.1% efficacy in symptomatic prevention from COVID-19 and in December 2020, received emergency use authorization from the US Food & Drug Administration (US FDA) for widespread immunization of people. Additionally, mRNA therapies, a rapidly growing class of medications for numerous diseases, will alter the accepted standard of service and advance customized medicine. As a result, the demand for mRNA-based products is anticipated to grow in the coming years.

Immediate Delivery Available | Buy this Premium Research Report@ https://www.novaoneadvisor.com/report/checkout/6847

Report Scope of the mRNA Therapeutics Market

This market growth is fueled by the rising prevalence of chronic diseases like cancer, heart disease, respiratory, CKD, and rare diseases like propionic acidemia, methylmalonic acidemia, glycogen disease, phenylketonuria, and metabolic and immune disorders. For instance, according to Globocan, in December 2020, there were 19.3 million new cases of cancer worldwide and 10 million cancer-related deaths were reported. Furthermore, the popularization of mRNA vaccines; the development of personalized therapeutics for cancer; and a strong pipeline of new products increase the demand for mRNA vaccines and therapeutics, thus propelling the industry growth during the projection period.

Increased investments by operating players for the production of advanced and effective therapeutics and vaccines are likely to support industry growth throughout the projected timeframe. For instance, in April 2021, in a joint venture with Axcelead, Inc., American mRNA therapeutic developer Arcturus Therapeutics formed a Japanese company in Chiba Prefecture and is constructing a production facility in Minamisoma City, Fukushima Prefecture. Such investments are likely to supplement the industry growth in the coming years.

Key Takeaways:

• By Type, the U.S. mRNA Therapeutics market was valued at USD 12.9 Billion in 2021 and expected to witness growth at a CAGR of 2.4% from 2022 to 2030.
• By application, the infectious diseases segment held a dominant share in 2021 owing to the increased patient population and awareness regarding infectious diseases
• By type, the prophylactic vaccines segment led the market in 2021. One of the key factors propelling the growth of the prophylactic vaccines business is the rising demand for prophylactic vaccinations, particularly the new COVID-19 vaccines
• By end-use, the hospitals and clinics segment captured the largest revenue share in 2021. The segment is being driven by the increasing number of patients visiting hospitals and clinics
• North America held the largest revenue share in 2021 owing to an increase in demand for COVID-19 mRNA vaccines, the existence of major players operating in the U.S., the availability of a technologically advanced healthcare research framework, and the presence of high R&D investment
• Europe is expected to grow significantly during the forecast period due to the rising occurrence of new diseases, which has prompted efforts for immunization against specific infectious diseases like COVID 19

Regional Insights

North America dominated the market with over 35.4% share in 2021 and will emerge as the fastest-growing region during the forecast period. The availability of significant research funding, expanding federal programs toward RNA-based medicines, and increasing number of clinical trials will drive the market in North America. For instance, in November 2020, The National Institutes of Health (NIH), the Defense Department, and federally funded academic laboratories have all supported Graham and others’ basic research, which has been a crucial component in the quick development of vaccinations against COVID-19. Since the pandemic started, the government has invested an additional $10.5 billion in vaccine manufacturers to quicken the delivery of their products.

Europe captured the second-largest revenue share in 2021 owing to the increased patient population and awareness regarding rare genetic diseases. Moreover, there are major players operating in Europe, and there is an increasing need for mRNA vaccines and therapeutics in the region to create transformational treatments. For instance, as part of the U.S. biotech’s expansion to “enable the delivery of mRNA vaccines and therapies locally,” Moderna is expanding its wings across Europe (Denmark, Belgium, the Netherlands, Poland, Norway, and Sweden), which will increase the demand for mRNA vaccines and further drive the market over the forecast period.

Some of the prominent players in the MRNA Therapeutics Market include:

• Moderna, Inc.
• BioNTech SE
• CureVac N.V.
• Arcturus Therapeutics
• Translate Bio, Inc.
• GSK plc.
• Argos Therapeutics Inc.
• Sangamo Therapeutics, Inc.
• Pfizer Inc.
• AstraZeneca plc.
• CRISPR Therapeutics AG

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global mRNA Therapeutics market

• Application
  • Rare Genetic Diseases
  • Oncology
  • Respiratory Diseases
  • Infectious Diseases
  • Others
• Type
  • Prophylactic Vaccines
  • Therapeutic Vaccines
  • Therapeutic Drugs
• End-use
  • Hospitals & Clinics
  • Research Organizations
  • Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Full Report is Ready | For Purchase Inquiry@ https://www.novaoneadvisor.com/report/checkout/6847

You can place an order or ask any questions, please feel free to sales@novaoneadvisor.com| +1 9197 992 333

Blog: https://www.novaoneadvisor.com/

Blog: https://www.visionresearchreports.com/

Blog: https://qyresearchmedical.com/